Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 17 de 17
Filtrar
1.
Poult Sci ; 96(8): 2831-2838, 2017 Aug 01.
Artículo en Inglés | MEDLINE | ID: mdl-28482031

RESUMEN

Salmonella contamination in chicken samples can cause major health problems in humans. However, not only the effects of antibiotic treatment during growth but also the impacts of the poultry slaughter line on the prevalence of Salmonellae in final chicken meat sold to consumers are unknown. In this study, we compared the isolation rates and antimicrobial resistance of Salmonellae among antibiotic-free, conventional, conventional Korean native retail chicken meat samples, and clonal divergence of Salmonella isolates by multilocus sequence typing. In addition, the distribution of extended-spectrum ß-lactamase (ESBL) genes in ESBL-producing Salmonella isolates was analyzed. A total of 72 retail chicken meat samples (n = 24 antibiotic-free broiler [AFB] chickens, n = 24 conventional broiler [CB] chickens, and n = 24 conventional Korean native [CK] chickens) was collected from local retail markets in Seoul, South Korea. The isolation rates of Salmonellae were 66.6% in AFB chickens, 45.8% in CB chickens, and 25% in CK chickens. By analyzing the minimum inhibitory concentrations of ß-lactam antibiotics with the disc-diffusion test, we found that 81.2% of Salmonella isolates from AFB chickens, 63.6% of isolates from CB chickens, and 50% of isolates from CK chickens were ESBL producers; all ESBL-positive isolates had the CTX-M-15 genotype. Interestingly, all ESBL-producing Salmonellae were revealed as ST16 by multilocus sequence typing and had the genetic platform of blaCTX-M gene (IS26-ISEcp1-blaCTX-M-15-IS903), which was first reported in Salmonellae around the world. The Salmonella ST33 strain (S. Hadar) isolated in this study has never been reported in South Korea. In conclusion, our findings showed that antibiotic-free retail chicken meat products were also largely contaminated with ESBL-producing Salmonellae and that their ESBL genes and genetic platforms were the same as those isolated from conventional retail chicken meat products.


Asunto(s)
Crianza de Animales Domésticos/métodos , Antibacterianos/farmacología , Farmacorresistencia Bacteriana , Microbiología de Alimentos , Carne/microbiología , Pruebas de Sensibilidad Microbiana/veterinaria , Salmonella/efectos de los fármacos , Animales , Proteínas Bacterianas , Pollos , Genes Bacterianos , Agricultura Orgánica/métodos , Prevalencia , República de Corea/epidemiología , Salmonella/aislamiento & purificación , beta-Lactamasas/análisis
2.
Skin Res Technol ; 23(2): 149-154, 2017 May.
Artículo en Inglés | MEDLINE | ID: mdl-27511708

RESUMEN

BACKGROUND/PURPOSE: Various methods have been used to objectively record skin changes. However, estimating the intrinsic and extrinsic aging of skin remains a challenge. Our objective was to study intrinsic skin aging with respect to patient age and extrinsic photo-aging of human dorsal (photo-exposed) and volar (photo-protected) forearm in vivo through skin auto-fluorescence (AF). We also examined the correlations between serum antioxidant enzyme, malondialdehyde(MDA), and skin AF. METHODS: 37 healthy volunteers were enrolled. We measured skin AF and its heterogeneity on the dorsal and volar forearms. We also examined serum concentration of catalase, superoxide dismutase, vitamin E, and MDA levels in every participant. RESULTS: In photo-protected areas, skin AF intensity in the 40 years or older group was significantly higher compared to the group less than 40 years-old. On the other hand, heterogeneity value was significantly higher in the less than 40 years-old group in photo-protected area. With respect to serum antioxidant enzyme and MDA level, only MDA level showed a negative correlation with skin AF intensity in photo-exposed area. CONCLUSION: We determined that skin AF intensity of the photo-protected area reflects intrinsic skin aging. In addition, degree of photo-aging could be indirectly inferred by skin AF of photo-exposed area and serum MDA level.


Asunto(s)
Catalasa/sangre , Malondialdehído/sangre , Imagen Óptica/métodos , Envejecimiento de la Piel/patología , Envejecimiento de la Piel/fisiología , Superóxido Dismutasa/sangre , Adulto , Anciano , Antioxidantes/análisis , Femenino , Humanos , Masculino , Persona de Mediana Edad , Proyectos Piloto , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Estadística como Asunto , Vitamina E/sangre , Adulto Joven
3.
Skin Res Technol ; 23(2): 169-175, 2017 May.
Artículo en Inglés | MEDLINE | ID: mdl-27511797

RESUMEN

BACKGROUND/PURPOSE: Treatment of atopic dermatitis (AD) and psoriasis requires their differentiation from other eczematoid dermatitis and a determination of disease severity. However, both can be clinically difficult and the findings subjectively interpreted. We investigated the utility of in vivo autofluorescence (AF) measurements for diagnosis of both diseases, and determination of severity. MATERIALS AND METHODS: Thirty patients with AD and 30 with psoriasis were recruited, together with sex- and age-matched patients with healthy skin. AF intensity was measured using the EcoSkin® fluorescence video dermatoscope. In AD and psoriasis patients, AF in non-sun-exposed lesional and non-lesional skin was measured. To identify the locations that reflect characteristics of AD, AF was also measured at the other sites in the patients with AD. RESULTS: AD was associated with lower AF and psoriasis with higher AF intensity peaking around 620 nm. In addition, skin AF intensity of each disease was associated with severity of lesion. CONCLUSIONS: Non-invasive measurement of skin AF in vivo can aid in diagnosis of AD and psoriasis as well as in treatment monitoring.


Asunto(s)
Dermatitis Atópica/patología , Dermoscopía/métodos , Interpretación de Imagen Asistida por Computador/métodos , Imagen Óptica/métodos , Psoriasis/patología , Adolescente , Adulto , Dermatitis Atópica/diagnóstico por imagen , Diagnóstico Diferencial , Femenino , Humanos , Masculino , Persona de Mediana Edad , Psoriasis/diagnóstico por imagen , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Adulto Joven
4.
J Endocrinol Invest ; 35(4): 413-8, 2012 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-21897114

RESUMEN

BACKGROUNDS: Signal transducer and activators of transcription-3 (STAT3) plays a critical role in promoting survival and cell growth as well as facilitating angiogenesis and metastasis in several cancers. AIM: This investigation focused on evaluation of STAT3 activities in human papillary thyroid cancers (PTC). METHODS: STAT3 activities of nuclear extracts of tumor tissue were measured from 35 PTC patients using enzyme- linked immunosorbent assay-based kits. RESULTS: STAT3 activities of PTC tissues were significantly lower than those of surrounding normal thyroid tissues [0.36 (interquartile range 0.24-0.72) vs 0.50 (0.29-1.11) arbitrary units, p<0.01]. We further analyzed the association between STAT3 activity and clinicopathologic factors in PTC tissue. Tumors with size ≥2 cm displayed significantly lower STAT3 activities than those <2 cm [0.25 (0.21-0.37) vs 0.53 (0.37-0.61) arbitrary units, p<0.01]. Notably, tumor size was inversely correlated with STAT3 activities in T1799A BRAF mutation-positive cases (Rs=-0.58, p<0.05), but not mutation-negative cases. CONCLUSIONS: STAT3 activities of PTC measured via DNA binding are suppressed in contrast to other human cancers. Tumor size larger than 2 cm is the only clinicopathologic parameter associated with low STAT3 activity. Moreover, tumor size appears inversely correlated with STAT3 activity, specifically in T1799A BRAF mutation-positive cases.


Asunto(s)
Carcinoma/metabolismo , Carcinoma/patología , Factor de Transcripción STAT3/metabolismo , Neoplasias de la Tiroides/metabolismo , Neoplasias de la Tiroides/patología , Adolescente , Adulto , Anciano , Carcinoma/genética , Carcinoma Papilar , Proteínas de Unión al ADN/genética , Proteínas de Unión al ADN/metabolismo , Femenino , Humanos , Masculino , Persona de Mediana Edad , Mutación/genética , Factor de Transcripción STAT3/genética , Cáncer Papilar Tiroideo , Neoplasias de la Tiroides/genética , Adulto Joven
5.
Cell Death Differ ; 17(4): 699-709, 2010 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-19851330

RESUMEN

Interferon regulatory factor-1 (IRF-1) is a transcription factor that acts as a tumor suppressor and causes apoptosis in cancer cells. We evaluated IRF-1-induced apoptosis in gastric cancer cell lines. We established stable clones in AGS cells that have a tetracycline-inducible IRF-1 expression system. We used these clones and recombinant adenovirus expressing IRF-1 to explore the mechanism of IRF-1-induced apoptosis in gastric cancer. Expression of IRF-1 causes apoptosis in gastric cancer cell lines as shown by phosphatidylserine exposure and cleavage of caspase-8, caspase-3, and Bid with the mitochondrial release of cytochrome c. However, inhibition of caspase-8 and Bid did not inhibit apoptosis and did not decrease cleaved caspase-9 or mitochondrial release of cytochrome c. We then show that IRF-1 upregulates PUMA (p53 upregulated modulator of apoptosis), which is known to activate apoptosis by the intrinsic pathway; this can be p53-independent. IRF-1 binds to distinct sites in the promoter of PUMA and activates PUMA transcription. Moreover, molecular markers of mitochondrial apoptosis are eliminated in PUMA knockout and knockdown cells and phosphatidylserine exposure is decreased dramatically. Finally, we show that IFN-gamma induces IRF-1-mediated upregulation of PUMA in cancer cells. We conclude that IRF-1 can induce apoptosis by the intrinsic pathway independent of the extrinsic pathway by upregulation of PUMA.


Asunto(s)
Proteínas Reguladoras de la Apoptosis/genética , Apoptosis/genética , Factor 1 Regulador del Interferón/genética , Proteínas Proto-Oncogénicas/genética , Neoplasias Gástricas/genética , Activación Transcripcional/genética , Apoptosis/fisiología , Proteínas Reguladoras de la Apoptosis/metabolismo , Proteína Proapoptótica que Interacciona Mediante Dominios BH3/metabolismo , Caspasas/metabolismo , Línea Celular Tumoral , Citocromos c/metabolismo , Regulación Neoplásica de la Expresión Génica/fisiología , Vectores Genéticos/genética , Humanos , Factor 1 Regulador del Interferón/metabolismo , Proteínas Mitocondriales/genética , Proteínas Mitocondriales/metabolismo , Fosfatidilserinas/metabolismo , Regiones Promotoras Genéticas/genética , Unión Proteica/fisiología , Proteínas Proto-Oncogénicas/metabolismo , Neoplasias Gástricas/metabolismo , Regulación hacia Arriba/fisiología
6.
Cell Death Differ ; 14(11): 1872-9, 2007 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-17657248

RESUMEN

Glioma tumor suppressor candidate region gene 2 (GLTSCR2/PICT-1) is localized within the well-known 1.4-Mb tumor suppressive region of chromosome 19q, which is frequently altered in various human tumors, including diffuse gliomas. Aside from its localization on the chromosome, several lines of evidence, such as PTEN phosphorylation, support that GLTSCR2 partakes in the suppression of tumor growth and development. However, much remains unknown about the molecular mechanisms of the tumor suppressive activity of GLTSCR2. The purpose of this study was to investigate the molecular mechanisms of GLTSCR2 in cell death pathways in association with its binding partner PTEN. In this work, we show that GLTSCR2 is a nucleus-localized protein with a discrete globular expression pattern. In addition to phosphorylating PTEN, GLTSCR2 induces caspase-independent PTEN-modulated apoptotic cell death when overexpressed. However, the cytotoxic activity of GLTSCR2 is independent of its ability to phosphorylate PTEN, suggesting that the GLTSCR2-induced cell death pathway is divergent from PTEN-induced death pathways. Our results suggest that the induction of PTEN-modulated apoptosis is one of the putative mechanisms of tumor suppressive activity by GLTSCR2.


Asunto(s)
Apoptosis , Núcleo Celular/metabolismo , Fosfohidrolasa PTEN/metabolismo , Proteínas Supresoras de Tumor/metabolismo , Línea Celular , Genes Supresores de Tumor , Humanos , Proteínas Nucleares/metabolismo , Fosforilación , ARN Interferente Pequeño/metabolismo , Proteínas Supresoras de Tumor/aislamiento & purificación
7.
Oncogene ; 26(44): 6420-30, 2007 Sep 27.
Artículo en Inglés | MEDLINE | ID: mdl-17452973

RESUMEN

Interferon (IFN) regulatory factor-1 (IRF-1) is a transcription factor that has apoptotic anti-tumor activity. In breast cancer cell types, IRF-1 is implicated in mediating apoptosis by both novel and established anti-tumor agents, including the anti-estrogens tamoxifen and faslodex. Here we demonstrate that in MDA468 breast cancer cells, apoptosis by IFN-gamma is mediated by IRF-1 and IFN-gamma, and IRF-1-induced apoptosis is caspase-mediated. IRF-1 induction results in cleavage of caspase-8, -3 and -7, and application of caspase inhibitors attenuate activated cleavage products. IRF-1-induced apoptosis involves caspase-8 since apoptosis is significantly decreased by the caspase-8-specific inhibitor IETD, c-FLIP expression and in caspase-8-deficient cancer cells. Furthermore, we demonstrate that IRF-1-induced apoptosis requires fas-associated death domain (FADD) since dominant-negative FADD expressing cells resist IRF-1-induced apoptosis and activated downstream products. Immunofluorescent studies demonstrate perinuclear colocalization of FADD and caspase-8. Despite the known role of FADD in mediating death-ligand induced apoptosis, neutralizing antibodies against classical death receptors do not inhibit IRF-1 induced apoptosis, and no secreted ligand appears to be involved since MDA468 coincubated with IRF-1 transfected cells do not apoptose. Therefore, we demonstrate that IRF-1 induces a ligand-independent FADD/caspase-8-mediated apoptosis in breast cancer cells.


Asunto(s)
Apoptosis/efectos de los fármacos , Neoplasias de la Mama/patología , Proteína de Dominio de Muerte Asociada a Fas/metabolismo , Factor 1 Regulador del Interferón/metabolismo , Interferón gamma/farmacología , Transducción de Señal , Receptor fas/metabolismo , Neoplasias de la Mama/metabolismo , Caspasa 3/metabolismo , Caspasa 8/metabolismo , Caspasa 9/metabolismo , Caspasas/metabolismo , Proteína de Dominio de Muerte Asociada a Fas/antagonistas & inhibidores , Proteína de Dominio de Muerte Asociada a Fas/genética , Técnica del Anticuerpo Fluorescente , Genes Dominantes , Humanos , Immunoblotting , Ligandos , Receptores del Ligando Inductor de Apoptosis Relacionado con TNF , Receptores del Factor de Necrosis Tumoral/metabolismo , Receptores Tipo I de Factores de Necrosis Tumoral/metabolismo , Fracciones Subcelulares , Ligando Inductor de Apoptosis Relacionado con TNF/metabolismo , Células Tumorales Cultivadas
9.
Curr Treat Options Oncol ; 1(4): 329-38, 2000 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-12057158

RESUMEN

Papillary thyroid cancer is the most common neoplasm of the thyroid gland. Surgical resection is the cornerstone of therapy. There is controversy regarding the extent of resection, ranging from thyroid lobectomy plus isthmusectomy to total thyroidectomy, but in experienced hands total thyroidectomy has many significant advantages over a lesser operation. Nonoperative therapy has no role as primary therapy for papillary thyroid cancer, but can be used in conjunction with surgery to improve outcome. Radioiodine in patients who have received total thyroidectomy can be used to identify residual occult tumor, recurrence, and metastasis, and can also be used to ablate the neoplasm, resulting in a substantial cure rate. Thyroid hormone is needed as replacement after total thyroidectomy, but can also be given as thyroid-stimulating hormone suppression, which may have an adjunctive benefit after resection.


Asunto(s)
Carcinoma Papilar/cirugía , Neoplasias de la Tiroides/cirugía , Carcinoma Papilar/tratamiento farmacológico , Carcinoma Papilar/radioterapia , Ensayos Clínicos como Asunto , Terapia Combinada , Humanos , Tasa de Supervivencia , Neoplasias de la Tiroides/tratamiento farmacológico , Neoplasias de la Tiroides/radioterapia , Tiroidectomía
10.
J Interferon Cytokine Res ; 19(7): 723-9, 1999 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-10454342

RESUMEN

We investigated the role of interferon (IFN) regulatory factor-2 (IRF-2) as an oncoprotein in vivo, opposing endogenous IFN-gamma suppression of tumor growth. Using syngeneic IFN-gamma knockout mice, we show that endogenous IFN-gamma slows growth of the mouse melanoma cell line B16-F10 in immunocompetent mice, suggesting that tumor cell resistance to IFN-gamma may lead to greater tumorigenicity. IRF-2 is a nuclear transcription factor induced by IFN-gamma that represses numerous IFN-inducible genes, including genes that regulate cell growth, in opposition to the transcriptional activator IRF-1. B16-F10 has a marked growth inhibitory response to IFN-gamma in vitro and has very little IRF-2 induction compared with other murine tumor cell lines. We engineered B16-F10 cells to stably overexpress murine IRF-2. In vitro, these transfected cells showed a marked resistance to the growth-inhibitory effect of IFN-gamma. In normal mice the IRF-2-transfected cells grew much faster than control tumors. In syngeneic IFN-gamma knockout mice, control cells grew at a rate similar to that of IRF-2-transfected cells, implicating resistance to endogenous IFN-gamma as playing the major role in enhanced growth of IRF-2-transfected tumors in intact mice. These experiments demonstrate that (1) IRF-2 enhances B16 melanoma growth and increases resistance to IFN-gamma in vitro, and (2) IRF-2 opposes the growth suppression mediated by endogenous IFN-gamma in vivo.


Asunto(s)
Proteínas de Unión al ADN/genética , Regulación Neoplásica de la Expresión Génica/fisiología , Interferón gamma/fisiología , Melanoma Experimental/metabolismo , Proteínas Oncogénicas/genética , Proteínas Represoras , Factores de Transcripción/genética , Animales , División Celular/fisiología , Células Clonales/metabolismo , Femenino , Inhibidores de Crecimiento/metabolismo , Factor 2 Regulador del Interferón , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Trasplante de Neoplasias , Transfección , Trasplante Isogénico , Células Tumorales Cultivadas
11.
Surgery ; 124(6): 1037-42, 1998 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-9854580

RESUMEN

BACKGROUND: Neuroendocrine tumors (NETs) are a potentially lethal component of multiple endocrine neoplasia type 1 (MEN 1). Somatostatin receptor scintigraphy (SRS) can be used to localize NETs and evaluate patients for extraduodenopancreatic disease; its utility in managing MEN 1 is undefined. METHODS: All patients with MEN 1 evaluated by SRS from April 1994 to November 1997 are reported. SRS findings were correlated with other imaging studies and operative findings. RESULTS: Thirty-seven SRS studies were performed in 29 patients with MEN 1. SRS identified occult tumor in 36% (4/11) of patients with only biochemical evidence of NET; 2 patients went on to resection. SRS showed tumor in 79% (15/19) of patients with computed tomography (CT)-demonstrated tumor; 30% (6/20) of the SRS lesions were occult on CT. Conversely, 55% (16/29) of CT-identified lesions were occult on SRS. SRS found distant disease in 21% (6/29) of patients. In patients who had previous operations, SRS found tumor in 40% (4/10) of patients, again with both new positive and false-negative results compared with other imaging. SRS also had 3 important false-positive results, including 1 patient who had laparotomy with no tumor identified. CONCLUSIONS: SRS is useful in identifying otherwise occult NETs in patients with MEN 1 and can substantially alter management. However, SRS also has significant false-positive and false-negative results that demand correlation with other studies.


Asunto(s)
Neoplasia Endocrina Múltiple Tipo 1/diagnóstico por imagen , Neoplasia Endocrina Múltiple Tipo 1/secundario , Octreótido/análogos & derivados , Ácido Pentético/análogos & derivados , Radiofármacos , Receptores de Somatostatina/análisis , Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Cintigrafía
12.
Ann Surg Oncol ; 4(4): 287-92, 1997 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-9181226

RESUMEN

BACKGROUND: Management of patients with mammary Paget's disease is controversial; recent recommendations range from primary radiotherapy to modified radical mastectomy. This review correlates associated breast findings with disease stage and outcome to help guide evaluation and treatment. METHODS: Retrospective review of clinical, mammographic and pathologic data from 38 women with mammary Paget's disease treated between 1979 and 1995 was performed. Mastectomies were performed on all but two patients with the entire breast and lymph nodes evaluated for histopathologic evidence of carcinoma. RESULTS: Underlying carcinoma (ductal carcinoma in situ and/or invasive ductal cancer) was found in most patients (92%) even when no palpable mass was evident (85%); this carcinoma is often multifocal (73%). Mammography fails to identify the underlying disease in many patients with no palpable mass and multifocal underlying disease (64%). Patients with Paget's disease and a palpable mass have a much greater incidence of invasive cancer, multifocal lesions, and positive lymph nodes, and have worse survival. CONCLUSIONS: Although some patients with Paget's disease might be well treated by breast conservation therapy, many patients have underlying multifocal carcinoma (including invasive cancer), which can be inapparent by examination and mammography. Selecting candidates with disease amenable to complete excision without mastectomy is problematic.


Asunto(s)
Neoplasias de la Mama/patología , Enfermedad de Paget Mamaria/patología , Adulto , Anciano , Anciano de 80 o más Años , Neoplasias de la Mama/diagnóstico por imagen , Neoplasias de la Mama/cirugía , Carcinoma in Situ/patología , Carcinoma Ductal de Mama/patología , Femenino , Humanos , Mamografía , Mastectomía , Persona de Mediana Edad , Pezones/patología , Enfermedad de Paget Mamaria/diagnóstico por imagen , Enfermedad de Paget Mamaria/cirugía , Estudios Retrospectivos
13.
J Immunol ; 158(3): 1284-92, 1997 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-9013971

RESUMEN

IFN-gamma has a direct antitumor effect on many tumor cell lines mediated through the IFN-gammaR. One effect of IFN-gamma is to induce the nuclear transcription factor IFN regulatory factor-1 (IRF-1), which may function as a tumor suppressor. In this study, mouse IRF-1 cDNA under a high constitutive expression promoter was transfected into the highly aggressive, nonimmunogenic MCA 101 murine sarcoma. Clones were obtained by G418 selection and screened for IRF-1 mRNA expression by reverse transcriptase-PCR (RT-PCR). High expression clones had high levels of two MHC class I proteins (H-2Kb and H-2Db) on the cell surface that correlated with increased levels of class I mRNA by RT-PCR. Furthermore, these clones also had increased levels of MHC class II protein (I-Ab), which correlated with increased levels of one subunit of class II mRNA by RT-PCR. IRF-1-expressing clones had markedly diminished cell growth in vitro and decreased anchorage-independent growth in a soft agar assay. These clones also demonstrated markedly prolonged tumor latency and slowed growth in syngeneic C57BL/6 mice. IRF-1 gene-transfected cells had shortened tumor latency and formed faster growing tumors in gamma-irradiated immunodeficient mice compared with results in immunocompetent mice. Mice immunized with IRF-1-transfected cells were protected against subsequent challenge with IRF-1 transfected cells and also demonstrated greater tumor latency and slower tumor growth against subsequent challenge with untransfected cells compared with mice immunized with empty vector-transfected cells. These studies demonstrate a tumor suppressor effect of IRF-1, which acts in vivo through both partial reversion of the malignant phenotype and enhanced immune recognition and may play a role in the antitumor effects of IFN-gamma.


Asunto(s)
Proteínas de Unión al ADN/uso terapéutico , Interferón gamma/fisiología , Fosfoproteínas/uso terapéutico , Sarcoma Experimental/inmunología , Animales , Adhesión Celular , División Celular , Proteínas de Unión al ADN/fisiología , Femenino , Expresión Génica , Técnicas de Transferencia de Gen , Genes MHC Clase I , Genes MHC Clase II , Antígenos H-2/inmunología , Antígenos de Histocompatibilidad Clase II/genética , Inmunoterapia , Factor 1 Regulador del Interferón , Ratones , Ratones Endogámicos C57BL , Fosfoproteínas/fisiología , ARN Mensajero/genética , Sarcoma Experimental/patología , Sarcoma Experimental/terapia , Factores de Transcripción/fisiología , Factores de Transcripción/uso terapéutico
14.
Ann Surg ; 223(6): 688-97; discussion 697-700, 1996 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-8645042

RESUMEN

OBJECTIVE: The authors evaluated the differences between stereotactic core needle biopsy (SCNBx) and needle localization surgical biopsy (NLBx) in cost and treatment course for patients with mammographically detected breast cancer. SUMMARY BACKGROUND DATA: Stereotactic core needle breast biopsy is a reproducible and reliable alternative to surgical biopsy for histologic diagnosis of mammographic lesions. METHODS: Records from 52 consecutive patients with invasive breast cancer diagnosed by SCNBx (n = 21) or NLBx (n = 31) over 2 years were reviewed. Episode-of-care costs were extracted from the Barnes Hospital billing system database. RESULTS: At the time of excision, surgical margins were statistically more frequently positive in patients treated with NLBx (55%) than patients treated with SCNBx (0%, p < 0.0001). Furthermore, patients in the NLBx group undergoing breast conservation surgery required re-excision more frequently (74%) than those in the SCNBx group (0%, p = 0.001). There were no complications in either group after the diagnostic procedure. All SCNBx results were correct in the diagnosis of invasive breast cancer. The median cost of SCNBx was approximately $1000 less than the median cost of NLBx. This cost difference was carried through the definitive procedure, whether it was breast conservation or mastectomy. CONCLUSIONS: This study shows the advantage of SCNBx to diagnose breast cancer and definitive operative care at a single procedure. The preoperative diagnosis of breast cancer eliminated positive operative margins and procedures to re-excise breast tissue. The use of SCNBx also saved approximately $1000 per patient compared with the use of NLBx. Our data suggest that SCNBx is the diagnostic procedure of choice for mammographically detected cancers.


Asunto(s)
Adenocarcinoma/patología , Biopsia con Aguja/métodos , Neoplasias de la Mama/patología , Técnicas Estereotáxicas , Adenocarcinoma/diagnóstico por imagen , Adenocarcinoma/economía , Anciano , Anciano de 80 o más Años , Biopsia con Aguja/economía , Neoplasias de la Mama/diagnóstico por imagen , Neoplasias de la Mama/economía , Costos y Análisis de Costo , Femenino , Humanos , Mamografía , Persona de Mediana Edad , Estudios Retrospectivos , Técnicas Estereotáxicas/economía
15.
J Virol ; 70(1): 165-71, 1996 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-8523521

RESUMEN

Induction of the cytopathic effect (CPE) in cells infected with poxvirus seems ubiquitous in that it has been associated with all different strains and preparations of poxviruses, regardless of the replicating status of these viruses. The study of the mechanisms by which CPE is induced by nonreplicating poxviruses is hampered by the lack of any noncytopathic mutant strains and preparations. In this paper, we report on the patterns of gene expression and induction of CPE by vaccinia viruses treated by limited cross-linking with psoralen and long-wave UV light (PLWUV). We show that treatment of cell-free virus with PLWUV could inactivate viral replication without abolishing the ability of the virus to infect cells. Viral transcription as indicated by reporter genes was generally enhanced and prolonged under early viral promoters and abolished under late promoters. Furthermore, increasing the levels of cross-linking with PLWUV resulted in a decrease and abolishment of viral expression of a large reporter gene and a concomitant loss of the induction of CPE. Cells infected with such a virus were able to express the reporter genes and proliferate. The generation of nonreplicating and noncytopathic recombinant vaccinia viruses may help in studies of the mechanisms of CPE induction by poxvirus and may facilitate the use of poxviral vectors in broader areas of research and clinical applications.


Asunto(s)
Reactivos de Enlaces Cruzados/farmacología , Efecto Citopatogénico Viral/efectos de los fármacos , Ficusina/farmacología , Regulación Viral de la Expresión Génica/efectos de los fármacos , Fármacos Fotosensibilizantes/farmacología , Rayos Ultravioleta , Virus Vaccinia/efectos de los fármacos , Animales , Línea Celular , Efecto Citopatogénico Viral/efectos de la radiación , ADN Viral/metabolismo , Genes Reporteros , Regiones Promotoras Genéticas , Transcripción Genética , Células Tumorales Cultivadas , Virus Vaccinia/genética , Virus Vaccinia/patogenicidad , Virus Vaccinia/efectos de la radiación , Replicación Viral/efectos de los fármacos , Replicación Viral/efectos de la radiación
16.
Cancer Res ; 55(21): 4765-70, 1995 Nov 01.
Artículo en Inglés | MEDLINE | ID: mdl-7585501

RESUMEN

We have constructed a recombinant vaccinia virus (recVV), vKT0334 mIL-12, containing the genes encoding the p35 and p40 subunits of murine interleukin-12 (mIL-12). In vitro experiments demonstrated that vKT0334 mIL-12 efficiently infected a variety of murine and human tumor cell lines and produced very high amounts (1.5 micrograms/10(6) cells/24 h) of biologically active mIL-12. Mice injected s.c. with 10(6) MCA 105 sarcoma cells, followed by injection at the same site with saline or a control recVV, vKT033, containing no mIL-12 genes, all developed progressively growing tumor, whereas 60% of animals injected with vKT0334 mIL-12 remained tumor free (P < 0.0005). Furthermore, tumor growth was significantly reduced in the remaining mice treated with vKT0334 mIL-12 that did develop tumor compared with mice treated with vKT033 (P < 0.03) or saline (P < 0.0001). We conclude that recVV expressing high levels of mIL-12 offers an effective in vivo method of cytokine gene delivery and expression in tumors with subsequent antitumor effect.


Asunto(s)
Interleucina-12/biosíntesis , Interleucina-12/genética , Neoplasias Experimentales/terapia , Neoplasias Experimentales/virología , Virus Vaccinia/genética , Virus Vaccinia/metabolismo , Proteínas Virales/genética , Animales , División Celular/efectos de los fármacos , Chlorocebus aethiops , Femenino , Humanos , Inmunoterapia , Interleucina-12/farmacología , Sustancias Macromoleculares , Ratones , Ratones Endogámicos C3H , Ratones Endogámicos C57BL , Proteínas Recombinantes/biosíntesis , Proteínas Recombinantes/genética , Proteínas Recombinantes/farmacología , Células Tumorales Cultivadas , Proteínas Virales/biosíntesis , Proteínas Virales/farmacología
17.
J Immunol ; 145(12): 4185-91, 1990 Dec 15.
Artículo en Inglés | MEDLINE | ID: mdl-2124237

RESUMEN

Potentially fatal physiologic and metabolic derangements can occur in response to bacterial infection in animals and man. Recently it has been shown that alterations in the levels of circulating cytokines such as IL-6 and TNF-alpha occur shortly after bacterial challenge. To understand better the role of IL-6 in inflammation, we investigated the effects of in vivo anti-mouse IL-6 antibody treatment in a mouse model of septic shock. Rat anti-mouse IL-6 neutralizing mAb was produced from splenocytes of an animal immunized with mouse rIL-6. This mAb, MP5-20F3, was a very potent and specific antagonist of mouse IL-6 in vitro bioactivity, demonstrated using the NFS60 myelomonocytic and KD83 plasmacytoma target cell lines, and also immunoprecipitated radiolabeled IL-6. Anti-IL-6 mAb pretreatment of mice subsequently challenged with lethal doses of i.p. Escherichia coli or i.v. TNF-alpha protected mice from death caused by these treatments. Pretreatment of E. coli-challenged mice with anti-IL-6 led to an increase in serum TNF bioactivity, in comparison to isotype control antibody, implicating IL-6 as a negative modulator of TNF in vivo. Anti-TNF-alpha treatment of mice challenged i.p. with live E. coli resulted in a 70% decrease in serum IL-6 levels, determined by immunoenzymetric assay, compared to control antibody, thereby supporting a role for TNF-alpha as a positive regulator of IL-6 levels. We conclude that IL-6 is a mediator in lethal E. coli infection, and suggest that antagonists of IL-6 may be beneficial therapeutically in life-threatening bacterial infection.


Asunto(s)
Infecciones por Escherichia coli/fisiopatología , Interleucina-6/fisiología , Choque Séptico/fisiopatología , Factor de Necrosis Tumoral alfa/toxicidad , Reacción de Fase Aguda , Animales , Anticuerpos Monoclonales/inmunología , Masculino , Ratones , Ratones Endogámicos BALB C , Análisis de Supervivencia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA